Pathos has successfully raised $345 million across multiple funding rounds, including a $283 million Series D round in April 2025, led by New Enterprise Associates and Revolution, which valued the Chicago-based company at $1.6 billion and marked its entry into the unicorn club. Pathos specializes in AI-driven drug discovery, leveraging real-world oncology data and patient-derived functional genomic data to optimize clinical-stage therapeutics, accelerate biomarker-driven drug development, and improve patient outcomes. Founded in 2022, the company has achieved unicorn status in just three years and four months.
Keep reading to explore Pathos’ funding journey, key investors, and what’s next for this innovative life sciences platform.
What Is Pathos and What Does It Do?
Founded in 2022, Pathos is headquartered in Chicago, Illinois, United States. The company offers an AI-based drug discovery platform, focusing on drug development, licensing, and co-development of clinical-stage therapeutics.
By optimizing patient selection strategies and leveraging real-world oncology and functional genomic data, Pathos identifies and validates compelling biology to develop efficacious drugs for patients with unmet medical needs. The platform aims to accelerate biomarker-driven drug development while enhancing patient outcomes.
How Much Funding Has Pathos Raised?
- Series D
- Amount Raised: $283M
- Date: April 17, 2025
- Lead Investors: New Enterprise Associates, Revolution
- Valuation at Round: $1.6B
- Motivation: To accelerate drug development, expand AI capabilities, and enhance patient outcome strategies.
Total Funding Raised: $345M
Key Investors
- New Enterprise Associates
- Details: Leading global venture capital firm investing across technology and healthcare.
- Investment Focus Areas: Life sciences, healthcare, technology
- Notable Investments: Robinhood, 23andMe, Snap
- Revolution
- Details: Venture capital firm focused on disruptive startups.
- Investment Focus Areas: Life sciences, healthtech, growth-stage technology
- Notable Investments: Zipline, Sweetgreen, CLEAR
Where Is Pathos’ Headquarters?
Pathos is headquartered in Chicago, Illinois, United States, providing access to top-tier research institutions, healthcare networks, and technology talent to drive innovation in AI-driven drug discovery.
What’s Next for Pathos?
Pathos plans to expand its AI-driven drug discovery platform globally, accelerate the development of clinical-stage therapeutics, and optimize patient selection strategies. Leveraging unicorn status and strong investor backing, the company aims to enhance its AI and genomic analytics capabilities, develop new drugs addressing unmet medical needs, and improve patient outcomes across oncology and other high-impact therapeutic areas.
Get Investor & Funding Insights with TexAu
TexAu provides detailed fundraising data on companies like Pathos. Track investors, monitor funding rounds, and gather actionable insights to strengthen your sales and business strategy.
Sign up for Free on TexAu and turn data into smarter, faster business decisions.
